EBM

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chessman, A. W
Right arrow Search for Related Content
PubMed
Right arrow Articles by Chessman, A. W
Evidence-Based Medicine 2005; 10:16
© 2005 BMJ Publishing Group Ltd.


Therapeutics

Review: anticonvulsants are better than placebo for reducing the frequency of migraine attacks

Chronicle E, Mulleners W. Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev 2004;(3):CD003226.

Q In patients with migraine, are anticonvulsants more effective than placebo for preventing or reducing the intensity of migraine attacks?

Clinical impact ratings GP/FP/Primary care *****{star}{star}IM/Ambulatory care ******{star} Neurology *****{star}{star}

Key Words: anticonvulsants • pain

The first 150 words of the full text of this article appear below.

METHODS
{ebmcmptrbooks.f1}Data sources: Medline (up to April 2003); the Cochrane Central Register of Controlled Trials (up to April 2003); review article references; books on headache; contact with drug companies, authors, and experts; and hand searches of Headache and Cephalalgia.

{ebmmgnfyglas.f1}Study selection and assessment: randomised controlled trials (RCTs) that compared anticonvulsants given regularly during headache free intervals in adults >18 years of age with placebo, no intervention, other drug treatments, or behavioural or physical therapies. Methodological quality was assessed using the Jadad 5 point scale.

{ebmruler.f1}Outcomes: headache frequency (number of migraine attacks measured at 28 d), headache index measures (frequency and intensity or duration), and adverse events.

MAIN RESULTS
15 RCTs met the selection criteria. Anticonvulsants investigated were divalproex sodium (500–1500 mg daily [4 RCTs]), topiramate (50–200 mg daily [3 RCTs]), sodium valproate (800–1500 mg daily [2 RCTs]), gabapentin (1200–2400 mg daily [2 RCTs]), carbamazepine (dose not reported [1 RCT]), clonazepam (1 mg . . . [Full text of this article]

Alexander W Chessman, MD

Medical University of South Carolina
Charleston, South Carolina, USA







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2005 by the BMJ Publishing Group Ltd.